Quest Diagnostics Inc (NYSE:DGX) has coverage initiated with a Neutral rating

ME Staff
-
0

Analyst Ratings For Quest Diagnostics Inc (NYSE:DGX)

Today, UBS Group initiated coverage on Quest Diagnostics Inc (NYSE:DGX) with a Neutral.

There are 10 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Quest Diagnostics Inc (NYSE:DGX) is Buy with a consensus target price of $105.20 per share, a potential 24.84% upside.

Some recent analyst ratings include

  • 1/17/2019-Quest Diagnostics Inc (NYSE:DGX) has coverage initiated with a Neutral rating
  • 1/3/2019-Quest Diagnostics Inc (NYSE:DGX) gets downgraded to Underperform by Bank of America
  • 12/2/2018-Quest Diagnostics Inc (NYSE:DGX) had its Buy rating reiterated by Credit Suisse Group with a $121.00 price target
  • On 7/10/2018 Everett Cunningham, SVP, sold 40,328 with an average share price of $112.00 per share and the total transaction amounting to $4,516,736.00.
  • On 7/2/2018 Everett Cunningham, SVP, sold 68,069 with an average share price of $109.67 per share and the total transaction amounting to $7,465,127.23.
  • On 5/29/2018 Jeffrey M Leiden, Director, sold 1,644 with an average share price of $105.61 per share and the total transaction amounting to $173,622.84.
  • On 5/25/2018 Mark Guinan, Insider, sold 61,533 with an average share price of $105.71 per share and the total transaction amounting to $6,504,653.43.
  • On 5/25/2018 Stephen H Rusckowski, Chairman, sold 168,490 with an average share price of $107.00 per share and the total transaction amounting to $18,028,430.00.
  • On 3/8/2018 Jon R Cohen, SVP, sold 83,669 with an average share price of $104.20 per share and the total transaction amounting to $8,718,309.80.
  • On 3/5/2018 Catherine T Doherty, SVP, sold 5,556 with an average share price of $101.00 per share and the total transaction amounting to $561,156.00.

About Quest Diagnostics Inc (NYSE:DGX)
Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Recent Trading Activity for Quest Diagnostics Inc (NYSE:DGX)
Shares of Quest Diagnostics Inc closed the previous trading session at 84.27 −0.78 0.91% with shares trading hands.